A study from the Centre for Psychedelic Research at Imperial College London has shown that extended DMT IV infusions are safe and well tolerated.
Beckley Psytech has confirmed it has dosed the first patient in its international Phase 2b study of BPL-003 – a novel synthetic intranasal formulation of 5-MeO-DMT...
Small Pharma has reported positive results from its study investigating the interaction of SSRIs and SPL026 – the company’s native DMT – in patients with Major...
Cybin Inc.
Dimethyltryptamine (DMT) is a naturally occurring psychedelic compound found in many plants and some animals.
A donation of $1.5 million has been gifted to the UC San Diego Psychedelics and Health Research Initiative to research DMT by philanthropist Eugene Jhong.
Algernon NeuroScience (AGN Neuro) has announced that its Phase 1 DMT trial is complete.
Cybin Inc.
Cybin has announced the completion of dosing the last subject in Part B of its three-part CYB004-E Phase 1 trial evaluating intravenous (IV) DMT in healthy...
The first patient in Beckley Psytech’s trial investigating its patent-protected benzoate formulation of 5-MeO-DMT – BPL-003 – as a therapy for Treatment Resistant Depression (TRD) has...